ArticleEuropean journal of pediatrics2015
Effect of glucocorticoids on growth and bone mineral density in children with nephrotic syndrome.
Article in European journal of pediatrics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Efficacy and safety of Huaiqihuang granule as adjuvant treatment for primary nephrotic syndrome in children: a meta-analysis and systematic review.World journal of pediatrics : WJP · 2021Pooled it
- IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2020Guideline
- The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients.Pediatric rheumatology online journal · 2019Trial
- Efficacy of low-dose daily versus alternate-day prednisolone in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial.Pediatric nephrology (Berlin, Germany) · 2019Trial
- The effect of vitamin D and calcium supplementation in pediatric steroid-sensitive nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2017Trial
- Bone mineral density using dual-energy X-ray absorptiometry in children with nephrotic syndrome: a cross-sectional study.International urology and nephrology · 2026Article
- Article
- Recombinant growth hormone for children with systemic lupus erythematosus and linear growth delay: A report of two cases and literature review.The Journal of international medical research · 2025Review
- Short Course of Systemic Steroids for Acute Respiratory Diseases During Infancy and Final Adult Height, Weight, and BMI: Preliminary Results from a Prospective Cohort Study.Journal of clinical medicine · 2025Article
- Is Childhood IgA Nephropathy Different From Adult IgA Nephropathy? A Narrative Review.Canadian journal of kidney health and disease · 2025Review
- Growth in children with nephrotic syndrome: a post hoc analysis of the NEPTUNE study.Pediatric nephrology (Berlin, Germany) · 2024Observational
- Impact of childhood nephrotic syndrome on obesity and growth: a prospective cohort study.Pediatric nephrology (Berlin, Germany) · 2024Article
- Article
- The long-term (five years) effects of prednisone therapy in children with frequently relapsing nephrotic syndrome: A controlled study of anthropometric parameters and metabolic abnormalities.Acta bio-medica : Atenei Parmensis · 2022Article
- Optimizing the corticosteroid dose in steroid-sensitive nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2022Review
- Systematic Review of Early Phase Pediatric Clinical Pharmacology Trials.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022Article
- Longitudinal growth patterns and final height in childhood-onset systemic lupus erythematosus.European journal of pediatrics · 2021Article
- Twelve-month outcome in juvenile proliferative lupus nephritis: results of the German registry study.Pediatric nephrology (Berlin, Germany) · 2020Article
- Bone Health in Glomerular Kidney Disease.Current osteoporosis reports · 2019Review
- Exogenous C-type natriuretic peptide therapy for impaired skeletal growth in a murine model of glucocorticoid treatment.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledGlucocorticosteroids (GCs) are the first-line treatment for idiopathic nephrotic syndrome (NS), but prolonged administration interferes with growth and bone mineralization. We conducted a retrospective study to analyze the long-term impact of prednisone on growth and bone mineral density (BMD) in children with NS. Data from children with NS followed during almost 10 years were analyzed. Height and spine BMD values were converted to Z-scores (standard deviation [SD]). The mean cumulative dose of GCs received was calculated and correlated to patient's growth and spine BMD using linear regression and subgroup analysis. We included 30 patients diagnosed at 3.7 years old (interquartile range (IQR) 2.6-4.8) and followed over 9.8 years (IQR 6.6-11.7). The one half of NS patients was steroid sensitive and one half dependent or resistant. The median cumulative dose of GCs received was 0.27 mg/kg/day (IQR 0.18-0.35). Growth and spine BMD were both negatively associated with the cumulative dose of GCs (P=0.001 and P=0.037, respectively). Final height Z-scores were significantly lower in patients receiving >0.2 mg/kg/day GCs (P=0.001). No difference was observed in spine BMD between subgroups.
conclusionIncreasing doses of GCs were significantly associated with lower height and BMD Z-scores. A significant effect on growth was observed with cutoff doses above 0.2 mg/kg/day.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.